TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

December 19, 2016

Primary Completion Date

April 29, 2019

Study Completion Date

April 29, 2019

Conditions
Mycosis FungoidesSézary Syndrome
Interventions
RADIATION

TSEB Therapy

TSEB is a type of radiation treatment in which the skin over the whole body is treated with electron radiation beams. All participants will receive the same standard TSEB dose and treatment schedule. During TSEB, patients are treated in a standing position on a rotating platform.

DRUG

Brentuximab vedotin

An antibody-drug conjugate (ADC) that targets CD30. A standard dose of brentuximab vedotin will be administered to all patients by intravenous infusion 3 weeks prior to initiation of TSEB and then every 3 weeks for 3 cycles.

Trial Locations (1)

23298

Virginia Commonwealth University/Massey Cancer Center, Richmond

All Listed Sponsors
collaborator

Seagen Inc.

INDUSTRY

lead

Virginia Commonwealth University

OTHER

NCT02822586 - TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome | Biotech Hunter | Biotech Hunter